Completed graduate studies, at the Graduate School of Engineering, The University of Tokyo. Completed Graduate School of Business Administration, Waseda University.
NanoCarrier Ltd., he was involved in the joint development of Nucleic Acid Drug with a major pharmaceutical company and was involved in a wide range of work from basic research to CMC. He then moved to JSR Corporation. As a new business development manager, he was mainly responsible for startup investments and collaborations related to mRNA, microbiome, synthetic biology, and genome editing. He also led the planning and operation of a startup incubation facility in the company's research laboratory.
He joined KII in 2023 as a Capitalist in charge of the medical and health area.